Therefore, despite the total number of CD8 TILs in T-lymphopenic mice not decreasing, the reduction in tumor-specific CD8 TILs appears to diminish responsiveness to ICB therapies, such as anti-PD-1. The gene discussed is PDCD1; the disease is neoplasm.